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Abstract 
Transthyretin (TTR) amyloidoses are familial or sporadic degenerative conditions often with heavy cardiac involvement. 
Presently, effective pharmacological therapy for TTR amyloidoses is not available mostly due to the substantial lack of 
knowledge on both the molecular mechanisms of TTR aggregation in tissue and the ensuing functional and viability 
modifications in aggregate-exposed cells. TTR amyloidoses are of particular interest for the relation between functional 
and viability impairment in aggregate-exposed excitable cells, such as peripheral neurons and cardiomyocytes. In 
particular, the latter cells provide the opportunity to investigate in parallel the electrophysiological and biochemical 
modifications when exposed for varying lengths of time to variously aggregated wtTTR, a condition that characterizes 
senile systemic amyloidosis (SSA).  
In this study we investigated biochemical and electrophysiological modifications in cardiomyocytes exposed to amyloid 
oligomers or fibrils of wtTTR or to its T4-stabilized form, which resists tetramer disassembly, misfolding and 
aggregation. The amyloid TTR cytotoxicity results in mitochondrial potential modification, oxidative stress, deregulation 
of cytoplasmic Ca2+ levels and Ca2+ cycling. The altered intracellular Ca2+ cycling causes a prolongation of the action 
potential performed by whole-cell recordings of action potential on isolated mouse ventricular myocytes which may 
contribute to the development of cellular arrhythmias and conduction alterations often seen in patients with TTR 
amyloidosis. 
Our data add information on the biochemical, functional and viability alterations in cardiomyocytes exposed to 
aggregated TTR providing clues on the molecular and physiological basis of heart dysfunction in sporadic (SSA) and 
familial (FAC) forms of TTR amyloidoses. 
. 
 
  
Abbreviations  
AFM: Atomic Force Microscopy 
FT-IR: Fourier transform infrared  
CR: Congo Red 
CTX-B: Cholera toxin B subunit 
MTT: 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
GM1: monosialotetrahexosylganglioside 
2-APB: 2-aminoethyl diphenylborinate 
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Introduction 
In the past years, misfolded proteins have been proposed to play a key role in the pathophysiology of several cardiac 
diseases in humans, including pathologic cardiac hypertrophy, dilated and ischemic cardiomyopathy. Actually, cardiac 
stress disorders, including dilated and hypertrophic cardiomyopathies are associated with the presence of soluble protein 
oligomers in cardiomyocytes (1). These data have led to suggest that protein misfolding and the ensuing proteotoxicity 
are important contributors to the establishment and progression of heart failure, and to parallel cardiac dysfunction as 
Alzheimer’s disease of the heart (2). Such knowledge has consolidated the idea that targeting the accumulation of 
misfolded proteins can be beneficial in patients with heart failure.  
Actually, several systemic amyloidosis display congestive heart failure and a variety of alterations in cardiac 
electrogenesis and conduction that contribute considerably to disease-associated morbidity and mortality (3, 4). Human 
transthyretin (TTR) is one of the proteins whose amyloid aggregates are often associated with heart disease. TTR is a 55 
kD homotetramer synthesized by the liver and the choroid plexus, which carries T4 and the retinol-binding protein in the 
plasma and cerebrospinal fluid (5). Extracellular aggregates of wild type TTR (wtTTR) are found in senile systemic 
amyloidosis (SSA), a condition affecting around 25% of the population over 80 years; a more severe phenotype 
characterizes familial amyloid cardiomyopathy (FAC), where TTR aggregation occurs as a consequence of any out of a 
number of described mutations in the TTR gene (6,7). Presently, an effective therapy against TTR amyloidosis is still 
lacking, and the most severe cases of SSA and FAC can be treated only by liver and, when the case, heart transplantation. 
Correspondingly, the molecular and functional mechanisms underlying wtTTR aggregation and toxicity in cardiac tissue 
remain ill-defined.  
Amyloid aggregation of TTR is preceded by tetramer destabilization into monomers/dimers with exposed hydrophobic 
surface and monomer/dimer misfolding, which results in structural reorganization into amyloid assemblies (8, 9). Most of 
the known TTR mutations in humans have been shown to be amyloidogenic favoring tetramer destabilization (10), 
whereas tetramer stabilization, as it occurs in some mutants such as the stable and non-amyloidogenic Thr119Met as well 
as following T4 binding, slows down the rate of dissociation of TTR tetramer, thus hindering fibril growth (11). The 
identity of the cytotoxic species associated with amyloid disease and in TTR amyloidosis is far from clear despite a 
plethora of studies in recent years. Several studies indicate that usually fibril deposition into amyloid aggregates is 
preceded by the appearance of toxic low molecular weight oligomeric aggregation nuclei (12,13) which impair cell 
viability notably by altering intracellular ion homeostasis (14-16), even though cell sufferance caused by nutrient shortage 
due to the physical barrier represented by the fibrillar burden can play an important role as well (17). Accordingly, TTR 
fibrils, previously considered direct responsible of tissue impairment in FAP/FAC and SSA, are now thought to be by far 
less toxic than their unstable oligomeric precursors that, presently, are considered the main responsible of cell damage and 
tissue functional impairment (18). Actually, it has long been thought that the mass of deposited amyloid fibrils was the 
sole responsible for tissue dysfunction. However, inflammation, apoptosis and ROS markers characteristic of tissue 
damage can be detected in human carriers of mutant TTR well before amyloid deposit appearance. These markers have 
been associated with amorphous TTR aggregates that can be observed in the early stages of disease evolution (18). 
Nevertheless, there is a substantial body of experimental evidence that fully demonstrates that amyloid fibrils are capable 
of causing cellular death in numerous situations (19-29). This raises the possibility that the molecular determinants 
underlying aggregate cytotoxicity may not always be associated with the same type of species, and that there can well be 
oligomers and fibrils with different structural and biophysical properties and hence with different abilities to interact with, 
disassemble, permeabilize and deregulate the cell membrane (30). Presently, very reduced information is available on the 
biochemical and cell modifications occurring in cardiomyocytes (CMs) exposed to aggregated TTR (32), whereas 
valuable knowledge does exist on the biochemical alterations and the occurrence of specific functional (e.g. 
electrophysiological) abnormalities resulting from exposure to toxic TTR amyloids of neuronal cells, with ensuing Ca2+ 
influx via TRPM8 and NaV1.8 channels (14). Furthermore, the possible involvement in these modifications of specific 
lipid clusters was inferred on the basis of some perturbation of Ca2+conductance (15). Both mechanisms are of potential 
relevance in CMs.  
In this study, we used HL-1 and primary mouse CM cultures exposed to aggregated wtTTR to investigate the features of 
aggregate-cell interaction and the ensuing electrophysiological and biochemical modifications resulting in cell functional 
and viability impairment. In particular, after a careful biophysical characterization of TTR aggregation in vitro, we 
investigated some electrophysiological alterations following cell exposure to TTR aggregates that recapitulate, in vitro, 
specific and crucial aspects of SSA in order to gather into a whole picture data on cell biochemical, functional and 
viability impairment provided by wtTTR at different stages of aggregation. As far as we know, our findings are the first 
reported on the biochemical and electrophysiological modifications occurring in CMs exposed to amyloid aggregates of 
wtTTR. Our data provide novel insights into the molecular and functional basis of heart pathophysiology in TTR 
amyloidosis. 
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Material and Methods 
 
wtTTR production 
Recombinant wtTTR was produced in a bacterial expression system using the E. coli BL21B DE3 (pLysS) strain. The 
expressed protein was purified by gel-filtration and ion exchange chromatography and its purity was checked by Agarose 
Gel and SDS PAGE. Native, T4-stabilized wtTTR (TTR-T4) was obtained by adding T4 to the wtTTR solution. Briefly, 
T4 was dissolved in DMSO (Sigma-AldrichSaint Louis, MO, US) at 1.0 mM concentration for 1 h at room temperature; 
then the solution was diluted in PBS containing wtTTR to a TTR:T4 ratio of 1:2. TTR oligomers (TTR-ol) and fibrils 
(TTR-fib) were generated by TTR incubation in 100 mM acetate buffer, pH 4.4 at 25 °C for 24 h or 96 h, respectively. In 
all experiments, aggregate concentration was expressed as soluble tetramer concentration.  
 
Congo Red (CR) assay and Fourier Transform- Infrared (FT-IR ) analysis 
Fibril growth was followed by CR assay and FT-IR analysis. The former was performed by mixing 133 μL of the protein 
solutions with 867 μL of a 10 mM phosphate buffer, pH 7.4, solution containing 20 μM CR and 150 mM NaCl. Solutions 
without protein or without CR were also prepared as controls. The CR absorption spectra were acquired after 2-3 min 
equilibration using an Ultrospec 2000 spectrophotometer (Pharmacia Biotech). 
The FT-IR spectra were collected in attenuated total reflection (ATR) on a protein hydrated film by a standardized 
approach (33, 34). Briefly, 3.0 µL sample aliquots were deposited on the singe reflection diamond plate of the Golden 
Gate ATR device (Specac, USA) and the spectra were collected after solvent evaporation. The 670-IR spectrometer 
(Varian Australia Pty Ltd., Mulgrave VIC, AU) equipped with a nitrogen-cooled Mercury Cadmium Telluride detector 
and an air dryer purging system, was used under the following conditions: 2.0 cm-1 spectral resolution, 25 kHz scan 
speed, 1000 scan co-additions, and triangular apodization. The second derivatives of the measured spectra were obtained 
by the Savitsky-Golay method using the Resolutions-Pro software (Varian Australia Pty Ltd., Mulgrave VIC, AU). The 
FT-IR spectrum of soluble TTR was collected at 40 µM protein concentration in 30 mM sodium phosphate buffer, pH 
7.4. For aggregation studies, the TTR spectra were recorded at 20 µM protein concentration in 100 mM acetate buffer, pH 
4.4.  
 
Dynamic Light Scattering (DLS) analysis  
Size distributions of the protein samples by volume were obtained after sample centrifugation (18,000 rpm for 10 min). 
The data were achieved by a Zetasizer Nano S DLS device (Malvern Instruments, Worcestershire, UK) using low volume 
disposable cells (12.5 × 45 mm). The temperature was maintained at 25 °C by a thermostated system. The acetate buffer 
was filtered immediately before use to clean off any impurity.  
 
Atomic Force Microscopy (AFM) and Transmission Electron Microscopy (TEM) analysis of TTR aggregates 
For AFM inspection, a 10 l aliquot of the sample was deposited on a freshly cleaved mica substrate and dried under 
mild vacuum. The AFM images were acquired in tapping mode in air using a Dimension 3100 SPM equipped with a ‘G’ 
scanning head (maximum scan size 100 m) and driven by a Nanoscope IIIa controller, or a Multimode SPM equipped 
with “E” scanning head (maximum scan size 10 m) and driven by a Nanoscope IV controller (Digital Instruments-
Bruker, Karlsruhe, Germany). Single beam uncoated silicon cantilevers (type OMCL-AC160TS, Olympus, Tokyo, Japan) 
were used. The drive frequency was in the 290-330 kHz range; the scan rate was in the 0.5-1.0 Hz range.  
For TEM analysis, sample aliquots were withdrawn from the aggregation mixture at regular time intervals to monitor the 
assembly process following adsorption onto formvar/carbon-coated 400 mesh nickel grids (Agar Scientific, Stansted, UK) 
and negative staining with 2.0% (w/v) uranyl acetate (Sigma-Aldrich Saint Louis, MO, US). The grids were observed at 
a 15-30000× magnification in a JEM 1010 transmission electron microscope at 80 kV excitation voltage.  
 
Dot blot assay 
5.0 µL samples of 10 µM wtTTR were spotted onto a nitrocellulose membrane and left to dry. Then the membrane was 
blocked with 3.0% BSA, 0.1% Tween-20 in TBS (50 mM Tris-HCl buffer, pH 7.5, 150 mM NaCl) for 1.0 h at room 
temperature, and incubated overnight at 4.0 C with rabbit anti-TTR polyclonal antibodies (1:2000) and with 
conformation specific antibodies: the rabbit anti-oligomer (A11) (1:10000) or the rabbit anti-fibril (OC) (1:5000) 
polyclonal antibody. After three washes in TBS/0.1% Tween-20, the membrane was incubated for 1.0 h at room 
temperature with peroxidase-conjugated anti-rabbit or anti-mouse antibodies (1:10.000). After three washes in TBS/0.5% 
Tween-20, the immunodetection was performed with the SuperSignal® West Pico chemiluminescent substrate and 
Kodak® Biomax MS film.  
 
HL-1 cardiomyocyte and human dermal fibroblast (HDF cell culture  
HL-1 cardiomyocytes were obtained from Dr W. C. Claycomb (Louisiana State University) and grown in T25, 
gelatin/fibronectin-coated flasks, as previously described (35). The cells were maintained in Claycomb Medium (JRH 
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Biosciences), supplemented with 10% fetal bovine serum (Life Technologies Italia fil., Monza – MB, Italy), 2.0 mM L-
glutamine (Life Technologies Italia fil., Monza – MB, Italy), 0.1 mM noradrenaline (Sigma-Aldrich Saint Louis, MO, 
US) and 100 U/mL penicillin-streptomycin (Life Technologies Italia fil., Monza – MB, Italy). At confluence, the cells 
were detached and re-plated at a 1:3 dilution in a new T25 flask or in 96 well plates and used for experimental 
measurements. HDF cells were cultured at 37°C with in complete medium (DMEM, 10% fetal bovine serum, 
3.0 mM glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin), in a humidified, 5.0% CO2 incubator. 
Every three days the cells (70-90% confluent) were detached and re-plated at a 1:3 dilution in a new plate or in 
96 well plates and used for measurements. 
 
Isolation of mouse ventricular myocytes 
Left ventricular cardiomyocytes were isolated from adult C57/6BL mice (Charles River, Wilmington, Massachusetts, US) 
by enzymatic digestion. Briefly, after heparin injection (5.000 U/mL) and anesthesia with isoflurane, the heart was rapidly 
excised, mounted on a Langendorff apparatus and perfused with perfusion buffer (see solutions) pre-warmed at 37 °C and 
equilibrated with 100% O2. Then, the solution was quickly changed to perfusion buffer plus Liberase DL (0.05 mg/mL, 
Roche Diagnostics, Indianapolis, US) and CaCl2 (12.5 μM). The left ventricle was excised, minced, and stirred in 
perfusion buffer containing CaCl2 (12.5 μM) and bovine serum albumin (1.0 mg/mL, Sigma-Aldrich Saint Louis, MO, 
US). The CMs were collected by gravity sedimentation, and stored in Tyrode’s solution containing 0.5 mM CaCl2 and 
4.0% penicillin–streptomycin solution, at room temperature. All recordings were completed within 4-6 h from the time of 
cell isolation.  
 
Calcium imaging  
Intracellular Ca2+ handling was evaluated as previously reported (36). Briefly, HL-1 and mice ventricular CMs were 
incubated for 20 min at 37 °C in Tyrode’s solution containing 1-5 L/L fluo-3-acetoxymethyl ester (FLUO-3 AM, 
Molecular Probes, Eugene, Oregon, US ) and 1.0 L/mL Pluronic F127 solution (Molecular Probes, Eugene, Oregon, 
US) for dye loading. The preparation was set in the stage of a fluorescence microscope (Leica DMIRE2) properly 
equipped for fluorescence signal production and detection. Fluo-3 was excited with the light of a xenon lamp (LPS 220; 
Photo Technology International), using a bandpass filter set at 480±15 nm. Fluo-3 fluorescence was detected at 540±15 
nm. Ca2+release from sarcoplasmic reticulum stores was studied using 5.0 μM ryanodine (Tocris Bioscience Missouri, US 
) or 5.0 μM 2-aminoethyl diphenylborinate (2-APB) (Sigma-Aldrich Saint Louis, MO, US), to block ryanodine and IP3 
receptors, respectively. Cardiomyocytes were pre-incubated with the inhibitors for 15 min before recordings. 
Experimental control of fluorescence acquisition was performed using the software Imaging Workbench (INDEC 
BioSystems). Data analysis was carried out using the Axon Imaging Workbench program (v2.2.1; Axon Instruments) or 
Metafluor (Molecular Devices, Sunnyvale, CA, US ). Ca2+cumulative content was evaluated in HL-1 CMs as integrated 
area under the curve after 20 min exposure to experimental condition and reported as mean fractional variation (±s.e.m) 
with respect to vehicle. Ventricular CMs were paced at 1.0 Hz 1-5 V (pulse duration 1.0 ms) and the Ca2+transients were 
analyzed to calculate amplitude, baseline level, time to peak, 50% and 90% decay times. The data were reported as mean 
fractional variation (±s.e.m) relative to the initial values measured for individual cells.  
 
Patch-clamp recordings 
Electrophysiological recordings were performed as previously reported (37). The cells were placed in a thermostatic bath 
on the platform of an inverted microscope (Nikon Diaphot TMD; Kawasaki, Japan). The patch-clamped cell was 
superfused by means of a temperature-controlled (36±0.5 °C) microsuperfuser, allowing rapid changes of the cell-bathing 
solution. Action potential recordings were performed using a patch amplifier (Axopatch 200B, Molecular Devices, 
Sunnyvale, CA, US ) in whole-cell configuration (current clamp mode) at 1.0 Hz and the signals were digitized via a 
DAC–ADC interface (Digidata 1200B, Molecular Devices, Sunnyvale, CA, US), acquired by means of pClamp software 
(version 10, Molecular Devices, Sunnyvale, CA, US), and analyzed using Origin 7.5 (GraphPad Software). The patch-
clamp pipettes, prepared from glass capillary tubes (Borosilicate GC150T, Harvard App, Saint-Laurent, Canada) by 
means of a two-stage puller (P-97, Sutter Instrument, California, US), displayed a resistance of 3.5-5.0 MΩ when filled 
with the internal solution. During the patch-clamp experiments, TTR aggregates were supplemented to the internal pipette 
solutions.  
 
Solutions for calcium imaging and electrophysiology 
Perfusion buffer (mM): NaCl 113, KCl 4.7, KH2PO4 0.6, Na2PO4 0.6, MgSO4 1.2, NaHCO3 12, KHCO3 10, HEPES 10, 
Taurine 30, BDM 10, D-(+)-glucose 10, pH 7.30.  
Tyrode’s solution (mM): D-(+)-glucose 10, Hepes 5.0, NaCl 140, KCl 5.4, MgCl2 1.2, CaCl2 0.0125, pH 7.3.  
Pipette solution (mM): K-Aspartate 130, Na2-ATP 5, MgCl2 2.0, CaCl2 5,0, EGTA 11, HEPES-KOH 10, pH 7.2,  
 
Reactive oxygen species (ROS) measurement 
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Intracellular ROS levels were determined using the fluorescent probe 2’,7’–dichlorofluorescin diacetate, acetyl ester 
(CM-H2 DCFDA)(Thermo Fisher Scientific, Molecular Probes Waltham, MA USA). CM-H2 DCFDA is a cell-permeant 
indicator for ROS that becomes fluorescent upon removal of the acetate groups by intracellular esterases and subsequent 
oxidation. The latter modification can be detected by monitoring the increase in fluorescence at 538 nm. The HL-1 cells 
were plated at a density of 10000 cells per well on 96-well plates. After 24 h of cell exposure to the aggregates (10 μM 
TTR monomer concentration), 10 μM DCFDA in DMEM without phenol red was added. After 30 min the fluorescence 
values at 538 nm were detected by Fluoroscan Ascent FL (Thermo Fisher Scientific, Molecular Probes Waltham, MA 
USA). 
 
Cell viability assay 
The cytotoxicity of the different forms of soluble or aggregated TTR was assessed by the MTT reduction inhibition assay. 
Briefly, the cells were plated at a density of 1500 cells/well on 96-well plates in 100 L culture medium. After 48 h, the 
medium was changed with 100 L of fresh medium containing the different TTR aggregates (10 μM monomer 
concentration) or with an equal volume of aggregation buffer (control cells). After 24 h, the cells were incubated for 2.0 h 
with 100 L of serum-free DMEM without phenol red, containing 0.5 mg/mL MTT. Finally, 100 L of cell lysis 
solution (20% SDS, 50% N, N-dimethylformamide) was added to each well; after sample incubation at 37 °C to allow 
complete lysis, the blue formazan absorbance was read at 570 nm with an automatic plate reader (Bio-Rad). Cell 
apoptosis was detected by the Annexin V-FITC Apoptosis detection kit (Sigma-Aldrich). A propidium iodide (PI) 
solution with Annexin V-FITC was used to discriminate among viable, apoptotic and secondary necrotic cells. Briefly, 
after a 24 h treatment with the TTR aggregates, the cells were incubated with Annexim V-FITC and PI for 10 min, at 
room temperature. Then the cells were analysed by flow cytometry, Cell viability was determined also using the trypan 
blue exclusion method. HL-1 cells were treated with TTR aggregates, after 24 h centrifuged at 200 × g and incubated in 
0.2% trypan blue (Sigma, St. Louis, MO) for 10 min at 37ºC. Cells were then washed in PBS and counted under phase-
contrast microscopy. In this assay, blue cells were concluded to have lost membrane integrity and were scored as 
nonviable. All counts were performed in triplicate. 
 
Sialic acid cleavage and quantification. 
The sialic acid moiety was removed from gangliosides as previously reported (38). Briefly, the cells were starved by 
incubation with DMEM serum-free media for 3.0 h at 37 °C and then left standing for 2.0 h in the presence of a mixture 
of neuraminidases from V. cholerae (11,7 mU) and C. perfringens (100 mU) (Sigma Aldrich Saint Louis, MO, US). 
The removed sialic acid was measured enzymatically by a specific kit (Roche Molecular Biochemicals Mannheim 
Germany) according to the manufacturer’s instruction. 
 
Mitochondrial membrane potential in living cells 
The change of the mitochondrial membrane potential (ΨM) in TTR-exposed cells (10 μM TTR monomer concentration) 
was detected by a fluorescence-based assay. The cells were cultured for 10 min at 37 °C on coverslips in Dulbecco’s 
modified Eagle’s medium containing 5.0 mg/mL of the lipophilic cationic probe (fluorochrome(5,5,6,6-tetrachloro-
1,1,3,3-tetraethylbenzimidazolcarbocyanine iodide) (JC-1 stain, Thermo Fisher Scientific, Waltham, MA USA). At 
hyperpolarized mitochondrial membrane potential (-140 mV), this dye forms a red fluorescent J-aggregate, whereas at 
depolarized membrane potential (-100 mV) it remains in the green fluorescent monomeric form. Prior to detection, the 
cells were washed in PBS and placed in an open slide-flow loading chamber mounted on the stage of a confocal scanning 
microscope (Bio-Rad) equipped with a krypton/argon laser source. The emitted fluorescence was monitored at 488 nm 
and 568 nm with a Nikon plan ApoX60 oil-immersion objective. Series of optical sections (512  512 pixels) were taken 
through the depth of the cells with a thickness of 1.0 µm at intervals of 0.8 µm. Twenty optical sections for each sample 
were projected as a single composite image by superimposition.  
 
Confocal immunofluorescence 
Sub-confluent HL-1 cells grown on glass coverslips were exposed to 10 μM TTR aggregates (monomer concentration) 
for 24 h. After incubation, the cells were washed with PBS and fixed in 2.0% buffered paraformaldehyde for 10 min. 
Then, the cells were counterstained with 50 µg/mL tetramethylrhodamine-conjugated wheat germ agglutinin (WGA) 
(Thermo Fisher Scientific, Molecular Probes Waltham, MA USA) for 45 min at room temperature, permeabilized by 
treatment with acetone at -20 °C for 1.0 min, washed with PBS and blocked with PBS containing 0.5% BSA and 0.2% 
gelatin. After counterstaining, the cells were incubated for 1.0 h at room temperature with an anti-TTR rabbit polyclonal 
antibody or with an anti-oligomer rabbit polyclonal antibody (A11) diluted 1:1000 and 1:10,000, respectively, in the 
blocking solution and then washed with PBS for 30 min under stirring. The immune reaction was revealed by Alexa488 
or Alexa568-conjugated anti-rabbit secondary antibody (Thermo Fisher Scientific, Molecular Probes Waltham, MA USA) 
diluted 1:400 in PBS. Finally, the cells were washed twice in PBS and once in redistilled water to remove any non-
specifically bound antibody.  
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Cell surface GM1 labeling was performed by incubating the cells with 10 ng/mL Alexa488-conjugated cholera toxin B 
(CTX-B) in complete medium for 20 min at room temperature. Cell fluorescence was imaged using a confocal Leica TCS 
SP5 scanning microscope (Leica, Mannheim, Ge) equipped with a HeNe/Ar laser source for fluorescence measurements. 
The observations were performed using a Leica Plan Apo X63 oil immersion objective, suited with optics for DIC 
acquisition. Series of 0.5 m thick optical sections (1024×1024 pixels) were taken through the cell depth at 0.4 m 
intervals and 20 optical sections for each examined sample were Z-projected. To quantify the immunofluorescence 
intensity of cell-associated TTR we randomly selected ten fields of view from three separate experiments. Co-localization 
analysis was performed by using developed algorithms such as the overlap coefficient according to Manders and the co-
localization coefficients k1 and k2 
 
                           
 
where S1 and S2 represent signal intensity of pixels in the channel 1 and 2, respectively. 
 
Data analysis and Statistics  
Statistical analysis was performed by means of Prism program (Graph Pad Software, U.S.A.) using the Student’s t test for 
grouped data or ANOVA followed by the Tukey's multiple comparison test for all other values. A probability value < 
0.05 was considered significant.  
 
Results 
 
Morphological analysis and biophysical properties of wtTTR aggregates 
The wtTTR assemblies TTR-T4, TTR-ol and TTR-fib grown at pH 4.4 at differing incubation times were first 
characterized by spectroscopic and morphological analysis. The conformational properties of TTR-T4 and aggregated 
TTR were initially investigated at pH 7.4 by FT-IR spectroscopy, which allows studying protein secondary structure and 
aggregation by the analysis of the IR absorption spectrum in the Amide I region (1700-1600 cm-1). TTR-T4 displayed the 
Amide I maximum around 1630 cm-1 (Fig. 1A), a signal resulting from the intramolecular β-sheet structure of the native 
protein (28). The second derivative of the spectrum (Fig. 1B) disclosed additional components at ~1691 cm-1, ~1675 cm-1, 
and ~1649 cm-1, that can be assigned to β-sheets, turns/β-sheets, and α-helical/random coil structures, respectively. At pH 
4.4, wtTTR fibrillized. At these conditions, after ~3 min  the peak at 1630 cm-1 assigned to the intramolecular β-sheet 
component slightly decreased in intensity and shifted to higher wavenumbers (Fig. 1A and 1B), suggesting partial 
unfolding/misfolding of TTR secondary structures, as reported for other proteins (33, 39). Prolonged incubation at pH 4.4 
resulted in the appearance of a downshift of the main β-sheet component indicating some rearrangement of the β-sheet 
contacts in the growing aggregates. After 96 h of incubation, the TTR spectrum displayed both a narrower Amide I band, 
as compared to that of the natively folded protein, whose maximum down-shifted to ~1624 cm-1 and a new well resolved 
component at ~1692 cm-1, characteristic of intermolecular -sheets in amyloid fibrils (40, 41). These modifications of the 
FT-IR spectra of wtTTR were not found at pH 7.4, where the spectra collected at different times of incubation were 
almost superimposable to that at T0 without apparent changes (Fig. 1C), and indicating protein stability. The different 
behavior of wtTTR at pH 4.4 and pH 7.4 were more evident when peak position of the main -sheet component was 
plotted against time (Fig. 1D); the plot was sharply modified only at the acidic pH.  
In the first 24 h of TTR incubation at pH 4.4, AFM and TEM imaging (Fig. 2A and 2B) showed the presence of 
differently-sized oligomeric structures (TTR-ol) 2.70.1 nm in height coexisting with short, worm-like prefibrillar 
assemblies of 3.50.1 nm in height. These protofibrils displayed a nodular morphology, resembling short chains of beads. 
Amyloid fibrils (TTR-fib) were not present at this aggregation time. Fibrils 5.7±0.1 nm in height appeared later, after 96 h 
of protein incubation. 
The transition from natively folded to oligomeric TTR was also investigated by DLS. An apparent hydrodynamic 
diameter (Dhapp) of about 7.0 nm was found for TTR-T4, which was consistent with its tetrameric structure (Fig. 2E) (42). 
However, following wtTTR incubation for 24h at acidic pH, larger oligomeric forms with a Dhapp of about 1000 nm 
appeared, which became prevalent with increasing time (Fig. 2E). 
To better investigate the nature of the oligomeric and fibrillar structures grown at these conditions, the aggregated TTR 
samples were analyzed by immunoblotting using the oligomer-specific A11 and the fibril-specific OC antibody. The A11 
antibody immunostained both TTR-ol and, to a lesser extent, TTR-fib sample while only TTR-fib showed a significant 
OC-immunoreactivity. In contrast, TTR-T4 did not exhibit any immunoreactivity either A11 or OC antibodies (Fig. 2C). 
The amyloid nature of TTR-ol and TTR-fib was further confirmed by the red-shift of the CR absorbance maximum, a 
signature of the amyloid fold (Fig. 2D). The shift was not observed in the TTR-T4 incubated at the same conditions (data 
not shown). 
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Immunolocalization of TTR aggregates  
After having described the structural features of TTR, both natively folded (TTR-T4) and under aggregating conditions 
(TTR-ol, TTR-fib), we sought to determine whether these different TTR species were able to interact with the plasma 
membrane of cultured HL-1 cells and the extent of the interaction. When the cells were exposed to the stabilized TTR-T4, 
we failed to detect any protein interaction with the cell membrane (Fig.3A), in agreement with recently reported data 
relative to the non-amyloidogenic, stabilized T119M variant (32); however, a significant association of TTR aggregates to 
cell surface was seen in HL-1 cells treated with TTR-ol or TTR-fib (Fig. 3B and 3C). Contrary to TTR-fib, TTR-ol was 
also found to be significantly internalized into these cells after 24 h exposure as shown by a representative magnified Y 
projection of a cell: TTR-fib was only observed in contact with the outer surface of the cell membrane (Fig. 3E) whereas 
TTR-ol was found in the cytoplasm as A11 immunopositive punctate fluorescence (Fig. 3D). The oligomers and fibrils 
association with cell membrane was evident (to a less extent for the fibril sample) also on human dermal fibroblast HDF 
as shown in Fig. S1 suggesting that TTR aggregates did not exhibit a distinct cellular specificity. However, in these cells 
was not evident any internalization of oligomeric species (Fig. S1). 
The role of the monosialoganglioside GM1, a major raft marker, in promoting aggregate-membrane interaction was also 
investigated. In fact, besides favoring peptide/protein misfolding and aggregation, recent data indicate that GM1 can also 
mediate the interaction of amyloid assemblies with the plasma membrane, notably by its negatively charged sialic acid 
component (27). Therefore, to further elucidate whether our TTR aggregates did interact with the cell membrane at GM1-
rich sites and the role of the negatively charged sialic acid moiety of GM1, we carried out confocal fluorescence 
microscopy experiments using a polyclonal antibody raised against wtTTR; the cell membrane was counterstained by 
Alexa 488-conjugated CTX-B, a fluorescent probe that binds predominantly GM1 on the cell membrane. In some 
experiments, the cells were treated with a mixture of neuraminidases (NAM) to specifically cleave sialic acid residues 
from the cell surface prior to aggregate exposure. Such treatment is milder respect to reducing membrane GM1 by 
treating cells with fumonisin or other inhibitors of GM1 synthesis since it maintains the GM1 backbone inside the bilayer 
and therefore does not perturb membrane lipid order. The treatment caused a significant decline (about 2.5-fold) of the 
sialic acid on HL-1 cells, as shown in Fig. 3H, without affecting cell viability (data not shown). At these conditions, we 
found that the signal of both TTR-ol and TTR-fib on the cell membrane was significantly reduced in NAM-treated cells 
(Fig.3F, 3G and 3I). The co-localization analysis by the Overlap Coefficient did not show significant differences between 
NAM-treated and NAM-untreated samples (Table. 1). Therefore, the ratio between the overlap coefficients k1 (weighted 
overlap of TTR immunofluorescence, red, to GM1 fluorescence) and k2 (weighted overlap of GM1 fluorescence, green, 
to TTR immunofluorescence) was used to determine the degree of GM1 recruitment in the co-localization areas (42). The 
analysis showed that in the cells treated with TTR-fib the k1/k2 ratio was lower than in the cells treated with TTR-ol, 
suggesting that TTR fibrils promote higher GM1 recruitment in the co-localization areas. When the cells were treated 
with NAM, the k1/k2 ratio increased but the total TTR immunofluorescence signal decreased as shown in Fig. 3I 
indicating that, in NAM-treated cells fibril/membrane interaction and GM1 clustering on the cell membrane are reduced. 
In conclusion, aggregate recruitment to the cell membrane was deeply dependent on the presence of negatively charged 
molecules, notably GM1, whose decrease affected much more fibril than oligomer binding.  
 
Taken together, these data confirm that TTR aggregates bind at the cell surface, thus favouring oligomer internalization; 
they also suggest that the interaction involves GM1 and occurs preferentially at its negatively charged moiety, 
highlighting the importance of electrostatic binding. Finally, our data agree previous studies indicating that TTR 
aggregates display high affinity for synthetic lipid membranes rich in anionic phospholipids (44). 
 
Aggregate cytotoxicity  
Once established that different wtTTR aggregates bind to membrane sites where sialic acid residues, notably those bound 
to GM1, are present and that binding is followed by internalization, in the case of oligomers, we tested whether such 
events modulated cell viability and caused distinct biological effects. Initially, we checked TTR cytotoxicity to HL-1 cells 
by the MTT reduction assay. As expected, TTR-T4 was harmless to exposed cells (Fig. 4A), similarly to the stabilized 
T119M mutant (32) whereas TTR-ol and TTR-fib displayed significant cytotoxicity, in agreement with their ability to 
interact with the plasma membrane (Fig.4A). We also compared the cytotoxic effect of TTR aggregates on HDF cells. 
These cells, despite the presence of aggregate on the membrane, resulted more resistant to amyloid insult (Fig.S1) 
suggesting a different vulnerability of varying cell types exposed to the same toxic aggregates. The decreased MTT 
reduction observed in HL-1 cells was not related to apoptotic or necrotic events (data not shown) suggesting that after 24 
h of exposure to TTR aggregates the HL-1 cells showed a significant impairment of mitochondrial functionality without 
cell death or activation of apoptosis. This finding was confirmed by the ROS-sensitive fluorescent probe CM-H2DCFDA; 
in fact, we found that incubation for 24 h with TTR-ol stimulated ROS production in HL-1 cells and that this effect was 
enhanced when the cells were exposed to TTR-fib (Fig.4B). We used the JC-1 dye to further confirm whether aggregate 
cytotoxicity was associated with mitochondria dysfunction, as previously shown for Aβ aggregates in Alzheimer’s 
disease (, 45). Therefore, we checked by confocal microscopy the effect on the mitochondrial membrane potential (Δψm) 
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of HL-1 exposure to TTR-T4 or to variously aged wtTTR aggregates. We found a significant, yet similar, decrease of 
Δψm in cells exposed to TTR-ol or to TTR-fib but not to TTR-T4 (Fig.4C and 4D), as shown by the disappearance of the 
red fluorescence and/or the increase of the green fluorescence. In particular, some cells were devoid of red fluorescence, 
which indicates loss of Δψm and severity of cell damage. These data indicate that, in HL-1 cells, the cytotoxicity of 
extracellular TTR oligomers and fibrils proceeds through adsorption to the plasma membrane and results in ROS 
generation and alteration of the mitochondrial membrane potential.  
 
Effect of TTR aggregates on cytoplasmic calcium levels in HL-1 cardiomyocytes  
It has previously been reported that both Ca2+ deregulation and ER stress contribute to TTR toxicity to neuronal cells (15, 
16). We therefore investigated whether some acute deregulation of cytoplasmic Ca2+ levels contributed to the early events 
following interaction of aggregated wtTTR with the sarcolemma and subsequent oligomer internalization. Typical 
experimental traces detected in quiescent HL-1 cells (i.e., not exhibiting spontaneous action potentials and associated 
intracellular Ca2+ oscillations) are reported in Fig 5A, which shows a slow, progressive increase of Ca2+ levels during 
acute cell exposure to the same concentration of either TTR-ol (grey trace) or TTR-fib (black trace). At all conditions, the 
Ca2+ concentration was sensitive to caffeine that, as expected, evoked a fast transient Ca2+ rise following depletion of 
sarcoplasmic reticulum (SR) stores. The cumulative Ca2+ content was calculated as integrated area under the curve 
recorded for 20 min and expressed as fractional variation (mean±s.e.m, Fig.5B) relative to vehicle. Ca2+ increase was 
statistically significant with respect to vehicle for both TTR-ol and TTR-fib but not for TTR-T4 (see Table S I for a 
detailed statistical analysis).  
Spontaneous calcium oscillations were observed in nearly one third of confluent HL-1 cells exposed to vehicle at 37 °C 
(Fig. 6A); as previously reported (45,46), oscillations appeared irregular in frequency, amplitude and duration (see inset 
of Fig. 6A). Estimated oscillations frequency values were 6.3±1.1 beats per minute (bpm) for cells treated with vehicle 
(n=19), 5.4±2.5 bpm for cells treated with wtTTR (n=14) and 5.9±1.5 bpm for cells treated with TTR-T4 (n=15). 
Notably, baseline calcium signal remained constant throughout the experimental interval with the vehicle as well as with 
wtTTR or TTR-T4 (Fig. 6B, K). Interestingly, both TTR-fib and TTR-ol did not produce any gross modification in 
oscillation frequency values, that were 6.3±1.2 bpm (n=11) and 5.6±1.5 bpm (n=17), respectively; however, similarly to 
quiescent HL-1 cells, both TTR-fib and TTR-ol clearly induced a net increase of baseline calcium signal, indicating a 
progressive accumulation of cytosolic calcium (Fig.6C, G). 
Considering that the rise of cytosolic Ca2+ in oligomer- and fibril-exposed cells resulted from aggregate interaction with 
the cell membrane and, possibly, oligomer internalization, we hypothesized that in cells exposed to TTR-ol, the 
internalized species gained access to the Ca2+ stores in the SR favoring Ca2+ exit to the cytosol, as previously shown for 
the ER in a mouse neuronal cell line (16). Therefore, we studied whether the Ca2+ deposits in HL-1 were sensitive to cell 
exposure to TTR-ol, TTR-fib and TTR-T4 by investigating the possible involvement of the ryanodine (Rya) and the IP3-
receptors, two well-known SR receptors that regulate Ca2+ handling in CMs. HL-1 cells were pre-incubated with 
ryanodine and 2-APB for 15 min to block ryanodine and IP3-receptors, respectively, before and during exposure to TTR-
ol, TTR-fib or TTR-T4. At these conditions, the rise of intracellular Ca2+ was significantly reduced (Fig.5B and Table S 
I), suggesting an involvement of the ryanodine and IP3-receptors and hence of the SR Ca2+ stores. In automatic HL-1 
cells, spontaneous calcium oscillations were eliminated by depletion of intracellular calcium stores with Rya and 2-APB 
(Fig.6E-N). Nonetheless, during Rya or 2APB treatment, TTR-ol or TTR-fib were still able to produce a modest yet 
visible raise of the baseline calcium signal (Fig.6E, J), in line with the effect observed in quiescent HL-1 cells (Fig.5B).  
It is known that amyloid oligomers permeabilize the plasma membrane of the exposed cells favoring uncontrolled Ca2+ 
entry from the extracellular milieu either non-specifically following disassembly of the membrane bilayer (48,49) and/or 
through the participation of specific Ca2+ channels (50,51). Therefore, we removed Ca2+ from the external solution to 
check whether and to what extent the CM plasma membrane, in addition to the SR one, was involved in intracellular Ca2+ 
rise induced by TTR aggregates. At these conditions, the rise of cytosolic Ca2+ in cells exposed to either TTR-ol or TTR-
fib was significantly reduced (Fig.5B and Table S I). Spontaneous calcium oscillations were also eliminated in automatic 
HL-1 cells by removal of external Ca2+ (Fig.6D-L), in agreement with previous data (47); similarly to what observed in 
not automatic HL-1 cells (Fig.5B), exposure to either TTR-fib or TTR-ol enhanced the baseline calcium signal (Fig.6D, 
H), Thus, Ca2+ influx from the extracellular medium and release from the internal stores both contribute to the 
cytoplasmic Ca2+ rise induced by prefibrillar  and fibrillar wtTTR. 
 
Effect of TTR aggregates on calcium cycling and action potential profile of mouse ventricular myocytes 
The enhanced intracellular Ca2+ levels in cells exposed to TTR-ol or TTR-fib led us to hypothesize that the presence of 
TTR aggregates could alter Ca2+ cycling and membrane potential during myocyte contraction. To test this hypothesis we 
measured Ca2+ transients in mice ventricular CMs during contraction evoked by electrical stimulation. As shown in Fig. 
7A, cell treatment with 10 μM TTR-ol increased Ca2+ transient amplitude after 5 min (b), 10 min (c) and 15min (d) 
exposure. At the same times mean fractional variations of Ca2+ transient amplitude (Fig.7B) in cells exposed to TTR-ol 
resulted significantly different from those detected in cells exposed to TTR-T4 or to vehicle. We observed a similar effect 
in cells exposed to TTR-fib; the effect arose in the same time window but its magnitude was significantly reduced as 
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compared to that seen in cells exposed to TTR-ol (see Table S II for statistical analysis). The reduced magnitude was 
consistent with the smaller cumulative calcium fractional variation induced by TTR-fib as compared to TTR-ol in HL-1 
cells. This finding agrees with the Ca2+ release from the internal stores and the Ca2+ flux from the extracellular medium 
seen in HL-1 cells (see above). Other parameters of Ca2+ transient (baseline level, time to peak and decay kinetics) were 
not modified (Tables SIII-S V and Table II). 
Finally, to assess the consequences of the altered intracellular Ca2+ cycling on membrane potential we performed whole-
cell recordings of action potential on isolated mouse ventricular myocytes by adding TTR-ol or TTR-fib to the pipette 
solution. At this condition, a clear prolongation of the action potential became evident 3 min after gaining whole-cell 
access that persisted after 7 min, and was characterized by a marked lengthening of the plateau phase (Fig. 7C). The 
observed effect on membrane potential is in line with the increase of cytosolic Ca2+ reported above and confirms the 
interference of oligomeric and fibrillar TTR with the electrophysiological properties of the investigated CMs. 
  
Discussion 
 
Cardiomyopathy is the most frequent and severe complication of TTR amyloidosis both in the familial (FAC) and in the 
senile (SSA) forms. The lack of effective pharmacological treatments for these conditions is, at least in part, the 
consequence of the reduced information on the key factors underlying TTR misfolding and aggregation in tissue as well 
as on the molecular features of the biochemical, functional and viability impairment of cardiac cells exposed to 
aggregated TTR. Presently, the cytotoxicity of amyloid aggregates, particularly those arising early in the aggregation 
path, is considered amongst the main factors responsible for cell functional and viability impairment (15, 49), even 
though cell sufferance can also result from the physical barrier to nutrient exchange represented by the fibrillar deposits 
(52).  
In this study, we investigated how different wtTTR forms, including the non-amyloidogenic, stabilized T4-bound 
derivative and amyloidogenic TTR including prefibrillar assemblies (TTR-ol) and mature fibrils (TTR-fib), affect the 
viability and some biochemical parameters in exposed CMs. These data were added to those provided by 
electrophysiological experiments on the early functional alterations occurring in exposed cardiac cells in terms of Ca2+ 
transients and membrane potential. In our experimental model, the TTR-fib sample contained a heterogeneous mixture of 
prefibrillar and fibrillar components as showed by DOT immunostaining. This sample makes sense if one considers that 
cardiac cells are exposed to tissue deposits where TTR is aggregated in the fibrillar form, and that oligomeric and/or 
protofibrils entities can also be present either as intermediates in the aggregation path (12, 13) and/or following leakage 
from the fibrillar deposits, as reported for other aggregated proteins (53).  
We initially characterized the aggregated forms used in this study by investigating in depth by FT-IR, CR, DLS and AFM 
the path of TTR aggregation at pH 4.4 or 7.4 as well as aggregate morphology. The aggregation of wtTTR, but not TTR-
T4, at pH 4.4 displayed the well-known path, where early oligomers are progressively replaced by mature fibrils as far as 
aggregation proceeds. The protein did not aggregate at pH 7.4, even for long incubation times, as previously reported 
(15). Then, we investigated whether, where, and how the different TTR aggregates were able to interact with the 
sarcolemma of the exposed cells. Prefibrillar TTR assemblies and TTR fibrils interacted with the plasma membrane of 
CMs and such interaction required the negatively charged sialic acid moiety of the ganglioside GM1, a key lipid raft 
component, even though we cannot exclude some contribution coming from the sialic acid residues bound to membrane 
glycoproteins. In this regard, there are some clear qualitative commonalities with data obtained in other cell types, namely 
neurons, and with aggregates grown from different peptides/proteins: amyloid aggregation and aggregate recruitment are 
favored by GM1-rich sites of the cell membrane (50, 54-55) and, more generally, by negatively charged surfaces (56-60). 
This observation can also provide clues to speculate that an increase in GM1 content in aged CMs could favor TTR 
aggregation in SSA, as previously shown in amyloid-positive synaptosomes from Alzheimer’s brains (56); however, as 
far as we know, data on GM1 content in aged CMs are not available. In our experimental condition, the colocalization 
analysis showed that fibrillar component promoted a higher GM1 recruitment than the prefibrillar component, suggesting 
a higher activity of the fibrils on cell membrane uptake by raft components and subsequent membrane damage. 
Accordingly, recent paper suggest that the amyloid toxicity is mediated by cellular factors that interact with protofibrils 
and fibrils inducing further protein fibrillization on the cell surface that, in turn,  triggers downstream a cascade of 
intracellular events compromising cell survival (30) . The importance of lipid rafts in TTR recruitment by the plasma 
membrane of the exposed cells is indirectly confirmed by a recent study reporting that a reduction of membrane 
cholesterol, a key component of lipid rafts, significantly impaired the interaction and subsequent internalization of two 
TTR variants (I122V and T119M) with the plasma membrane of exposed CMs (the AC16 line) (32). Even though the 
authors exposed cells to soluble, non-aggregated proteins, they are aware of the problem to assess which precise TTR 
species are involved in cell damage. They speculated about the possibility that the samples of their soluble amyloidogenic 
V121I TTR contained tiny amounts of oligomer populations that would interact preferentially with the exposed cells. If 
so, their condition would resemble our well-controlled approach. 
TTR-ol and TTR-fib displayed significant cytotoxicity, but they did not result in cell death at our conditions, in 
accordance with their ability to interact with the plasma membrane, to be internalized (in the case of TTR-ol), to induce 
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intracellular ROS production, to alter intracellular Ca2+ homeostasis and mitochondrial membrane potential. The latter 
effects were, at least in part, the consequence of membrane permeabilization to calcium; in fact, increase in intracellular 
Ca2+ concentration and mitochondrial membrane potential perturbation were not seen in cells cultured in Ca2+-free 
medium or exposed to the stabilized TTR-T4, unable to bind to the plasma membrane. The hampered Ca2+ rise in cells 
treated with inhibitors of the ryanodine and IP3-receptors before exposure to aggregated TTR suggests that such an 
increase depends, at least in part, on the release from SR stores through either receptor. Similar findings were previously 
reported in mouse neuronal cells exposed to TTR oligomers (16), suggesting the existence of shared basic alterations 
induced by TTR aggregates in different cell types and a possible pathophysiologic basis for multi-organ failure in TTR 
amyloidosis. In our model, it is possible that the increased Ca2+ initially came from the extracellular medium and only 
subsequently from the intracellular stores by Ca2+-induced calcium release (CICR), an important mechanism of Ca2+ 
handling in cardiac cells (61). We cannot exclude that the effects at the mitochondrial and SR membrane result, at least in 
part, from the interaction with the internalized oligomers; however, the same effects were also found in cells exposed to 
TTR-fib, where intracellular oligomers were absent. More likely, the mitochondrial membrane depolarization could result 
from the increased levels of free intracellular Ca2+, as reported in other cases (62). In the case of TTR-fib, which does not 
penetrate inside the cells, a different mechanism, either alternative or additive, can be hypothesized; this could involve 
fibril interaction with death receptors or Ca2+ channels, as previously shown for amyloid fibrils grown from Sup35NM 
(27) or ataxin-3 (50). This scenario supports the idea that, in TTR amyloidosis, same disturbance of cell/tissue function by 
the deposits of fibrillar material results not only from mechanical alteration of proper oxygen and nutrients exchange, but 
also from more subtle biochemical and physiological modifications resulting from the interaction of deposited fibrils 
and/or leaked oligomers with surrounding cells. Several lines of evidence implicate amyloid oligomers as the main 
cytotoxic species, even though not all oligomers are indeed cytotoxic (63, 64); however amyloid fibrils cytotoxicity is not 
surprising since it has been repeatedly reported (19-23). In addition, given the high complexity of the fibrillation process 
and considering the overall dynamics in the assembly and disassembly of toxic amyloid species, the possibility that 
toxicity is displayed by different conformers should not be disregarded; moreover, it has also been suggested that the 
ongoing aggregation process rather than a clearly defined aggregate is responsible for amyloid toxicity (30, 31).  
Our findings on Ca2+dyshomeostasis in exposed CMs reveal the occurrence of early effects, which likely precede or 
parallel those affecting cell viability and mitochondrial physiology. In cell culture all these effects develop within minutes 
from cell exposure to the aggregates, as shown by the temporal dynamics of Ca2+ levels and action potential recordings. A 
similar time course of cytoplasmic Ca2+ increase has been reported in peripheral sensory neurons exposed to TTR 
aggregates, where the effects were mediated by a gain of function of different ion channels, namely voltage-gated calcium 
and sodium channels and transient receptor potential M8 channels (14). Assessing whether in our setting the enhanced 
intracellular Ca2+ results from similar modifications deserves further investigation. In line with this observation, our 
findings on perturbation of intracellular Ca2+ homeostasis do not exclude or may also concur with multiple modifications 
of different ion channels and/or pumps, which altogether contribute to define the functional profile of CMs. However, a 
comprehensive exploration of each specific ionic modification potentially induced by TTR variants requires dedicated 
investigations beyond the aims of the present study. Interestingly, in sensory neurons one of the mechanisms supposed to 
explain Ca2+ rise is TTR interaction with cholesterol-rich regions of membranes able to promote ion channel opening. 
Such a hypothesis is in line with previous findings (32, 57, 65) and with our present data showing a preferential 
interaction of TTR aggregates with GM1-rich sites, presumably in lipid rafts. Of note, GM1-rich sites have been shown to 
co-localize with, and to modulate, ion channel function in the plasma membrane of different cell types (66-71) and with 
the sodium calcium exchanger in the nuclear envelope of cardiomyocytes (72).  
Besides cell viability and mitochondrial efficiency, the increase in Ca2+ transient amplitude observed in electrically-
stimulated ventricular CM exposed to TTR aggregates are in agreement with their ability to mobilize cytosolic Ca2+  
Indeed, in CMs a complex network involving plasmalemma, SR receptors (namely ryanodine but also IP3 receptors) and 
mitochondria is responsible to finely tune cytosolic Ca2+ (73-75). In this interplay, the mitochondria serve as an efficient 
dynamic buffer of the Ca2+ released during contraction. The interplay, inside cells, between oxidative metabolism, 
calcium levels, ATP and ROS production and protein aggregation has been previously outlined (75). It is possible that 
ionic mechanisms accomplishing this function at the mitochondrial membrane are impaired by TTR aggregate-induced 
membrane depolarization, thus contributing to cytoplasmic Ca2+ rise. Whatever the source of Ca2+ accumulation inside the 
CMs, this effect is expected invariably to have relevant consequences in terms of generation and propagation of electrical 
impulses. Indeed, an increase in intracellular calcium concentration is a common feature of several acquired or congenital 
cardiomyopathies: for sake of comparison, a 40% increase in diastolic Ca2+ level was measured in cardiomyocytes from 
patients with hypertrophic cardiomyopathy, compared to control cells (76). Such an increase is sufficient to predispose 
cardiomyocytes to contractile dysfunction and occurrence of arrhytmogenic mechanisms (75). Accordingly, action 
potential recordings in mouse ventricular myocytes exposed to TTR aggregates show a remarkable prolongation of 
repolarization with a pronounced increase of the plateau level. Both events are suggestive of increased cytosolic Ca2+ 
levels, in agreement with our findings on TTR aggregate-induced Ca2+ accumulation and with previous studies in isolated 
CMs (77).  
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Conclusion 
Taken together, the alterations of the mechanisms controlling intracellular Ca2+ homeostasis and the prolongation of the 
duration of the action potential may alter the functional properties of CMs favoring the development of cellular 
arrhythmias. These effects, besides further supporting the idea that specific cellular abnormalities are induced by TTR 
aggregates in the heart parenchyma, may also represent a basis for the occurrence of rhythm disturbances and conduction 
alterations often seen in patients with TTR amyloidosis. 
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FIGURE LEGENDS 
FIGURE 1. Characterization of wt TTR by FT-IR. A: FT-IR absorption spectra of native TTR and of TTR incubated at 
pH 4.4 for different time lengths. B: Second derivatives of the absorption spectra reported in (A). C: Second derivatives 
of the absorption spectra of TTR incubated at pH 7.4 for different lengths of time. The peak positions of the main 
components are also given. The spectra are reported after normalization to the Amide I band area. D: Peak positions 
(taken from the second derivative spectra) of the main -sheet component reported versus incubation time at pH 7.4 or 
pH 4.4.  
 
 
 
 
 
FIGURE 2. Morphological characterization of TTR aggregates. A: AFM images of TTR-T4, TTR-ol and TTR-fib. 
Scan size 1.0 m. B: TEM images of TTR-T4, TTR-ol and TTR-fib (scale bar 200nm). C: Dot blotting of TTR-T4, TTR-
ol and TTR-fib using anti-conformational A11 and OC antibodies. Three replicates were generated and probed separately 
by anti-TTR, A11 and OC antibody. D: Congo Red absorption spectra of TTR-T4 (green line), TTR-ol (red line), TTR-fib 
(blue line). E: DLS analysis of TTR-T4, TTR-ol and TTR-fib. Volume distribution of the particle apparent hydrodynamic 
diameter. 
 
 
 
 
 
FIGURE 3. Confocal analysis. Confocal images of HL-1 cells treated with wtTTR. The cells were exposed for 24 h to 
10 M (A) TTR-T4, (B) TTR-ol and (C) TTR-fib. D-E: z-projections. F-G: HL-1 cells pretreated with neuraminidases to 
reduce sialic acid on the cell surface and incubated for 24 h to 10 M TTR-ol (F)  and  TTR-fib (G). The cells were 
stained with cholera toxin (green) and then were fixed, permeabilized and stained with anti-TTR antibody (red) or A11 
antibody (red). H: Sialic acid quantification. HL-1 cells were treated with 11,7 mU.I. of V. cholera neuraminidase and 5.0 
mU.I. of A. urefaciens neuraminidase for 1.0 h at 37 °C in serum-free medium The sialic acid levels in the membrane 
fractions were analyzed enzymatically by sialic acid quantification kit. * p< 0.05. I: Quantitative analysis of TTR-binding 
on the cells. Each graph displays the mean values ± SE and a statistical comparison between treated and TTR-T4-treated 
cells n= 5, (* p< 0.05, °p<0.01, #p<0.001). 
 
 
 
FIGURE 4. Cell viability, ROS levels and mitochondria dysfunction: A-B-C: Cytotoxicity of TTR-T4, TTR-ol and TT-
fib to human HL-1 cells performed by MTT reduction assay (A), intracellular ROS production (B), JC-1 assay (C). D: 
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Quantification of  Δψm  expressed as a ratio (J-aggregates/monomer) in the different treatment groups. The values shown 
are normalized against the buffer control (n=3, mean ±s.d.). The statistic was analysed by unpaired Student’s t-test 
(**p<0.01, ***p<0.001). 
 
 
 
FIGURE 5. Effect of different TTR samples on cytoplasmic calcium levels in HL-1 cardiomyocytes. A: Time course of 
cytosolic Ca2+ signal detected in HL-1 CMs exposed to 10 µM TTR-ol or TTR-fib (monomer concentration) for 20 min 
before SR depletion with 10 mM  caffeine. B: Mean fractional variation (±standard error of the mean) relative to vehicle 
of cumulative cytosolic Ca2+ calculated after 20 min exposure to different experimental conditions. Abbreviations: Veh, 
vehicle; TTR-ol, oligomeric transthyretin; TTR-fib, fibrillar transthyretin; TTR-T4, native TTR complex with thyroid 
hormone; TTR-ol 0 Ca, oligomeric TTR in Ca2+-free medium; TTR-fib 0 Ca, fibrillar TTR in Ca2+-free medium; TTR-ol 
Rya, oligomeric TTR plus ryanodine; TTR-ol 2APB, oligomeric TTR plus 2APB; TTR-fib Rya, fibrillar TTR plus 
ryanodine; TTR-fib 2APB, fibrillar TTR plus 2APB. Statistical analysis (ANOVA followed by Tukey's multiple 
comparisons test) is reported in Table S I. 
 
 
 
FIGURE 6. Effect of different TTR samples on cytoplasmic calcium levels in automatic HL-1 cardiomyocytes. A: 
Time course of cytosolic Ca2+ signal detected in automatic HL-1 CMs exposed to Vehicle (A),  10 µM TTR (B), TTR-ol 
(C), TTR-ol in Ca2+-free medium (D), TTR-ol plus ryanodine (E), TTR-ol plus 2APB (F), TTR-fib (G), TTR-fib in Ca2+-
free medium (H), TTR-fib plus ryanodine (I), TTR-fib plus 2APB (J),  TTR-T4 (K), TTR-T4 in Ca2+-free medium (L), 
TTR-T4 plus ryanodine (M), TTR-T4 plus 2APB (N), for 20 min before SR depletion with 10 mM caffeine. 
Abbreviations: Veh, vehicle; TTR-ol, oligomeric transthyretin; TTR-fib, fibrillar transthyretin; TTR-T4, native TTR 
complex with thyroid hormone; TTR-ol 0 Ca, oligomeric TTR in Ca2+-free medium; TTR-fib 0 Ca, fibrillar TTR in Ca2+-
free medium; TTR-T4 0 Ca, TTR-T4 in Ca2+-free medium; TTR-ol Rya, oligomeric TTR plus ryanodine; TTR-ol 2APB, 
oligomeric TTR plus 2APB; TTR-fib Rya, fibrillar TTR plus ryanodine; TTR-fib 2APB, fibrillar TTR plus 2APB; TTR-
T4 Rya, TTR-T4 plus ryanodine; TTR-T4 2APB, TTR-T4 plus 2APB.  
 
 
 
FIGURE 7. Effect of TTR variants on calcium transient and action potential of mouse ventricular myocytes. A: 
Representative fluorescence signals measured from ventricular CMs loaded with Fluo-4 and stimulated at 1.0 Hz pacing 
frequency during exposure to oligomeric TTR for 0 (a), 5 (b), 10 (c), 15 (d) and 20 (e) min. B: Time course of Ca2+ 
transient amplitude variation, expressed as mean fractional variation (± standard error of the mean) relative to time zero 
amplitude in ventricular CMs exposed to vehicle (n=18), oligomeric (n= 13), fibrillar (n=19) and wtTTR(n=14).  
Statistical analysis (ANOVA followed by Tukey's multiple comparisons test) is reported in Table S II. C: Representative 
action potential profiles measured from ventricular CMs recorded in whole-cell configuration (1.0 Hz pacing frequency) 
immediately after seal rupture (a and d) and after 3 or 7  min exposure to pipette solution containing 1.0 µM TTR-ol (b 
and c) or TTR-fib (e and f).  
 
 
 
 
 
Table I: Co-localization analysis of TTR oligomers/fibrils and GM1 on the plasma membrane of HL-1 
cardiomyocytes. 
 
 TTR-ol TTR-fib TTR-ol + NAM TTR-fib + NAM 
Overlap Coefficient 0.895 0.899 0.839 0.850 
k1/k2  0.855 0.448 3.070 2.56 
 
 
 
Table II: 90% decay time fractional variation of calcium transient relative to initial value in mice ventricular 
cardiomyocytes  
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Time 
(min) 
Vehicle (mean±s.e.m.) 
n=18 
TTR  
(mean±s.e.m.) 
n=13 
TTR-ol 
(mean±s.e.m.) 
n=14 
TTR-fib 
(mean±s.e.m.) 
n=19 
0 1.1·10-6±9.1·10-7 2.0·10-7±3.1·10-7 8.3·10-7±1.0·10-6 4.4·10-8±1.9·10-7
5 15.7±12.3 -7.5±8.7 14.0±12.6 10.4±3.9 
10 13.9±12.0 1.3±10.3 17.0±15.3 13.2±5.1 
15 30.1±18.0 16.2±10.3 40.2±23.3 25.4±10.9 
20 122.4±31.4 115.7± 25.8 202.8±81.4 122.3±25.1 
 
 







 
FIGURE  S1. Effect of TTR variants on HDFα human cells.  Confocal images of Human dermal 
fibroblast (HDFα) exposed for 24 h to protein buffer (A), 10 μΜ TTR-T4 (B), TTR-ol (C) and TTR-fib (D). 
The cells were stained with cholera toxin (green) and then were fixed, permeabilized and stained with anti-
TTR antibody (red).  1,2: z-projection of the ROIs selected. E: Cytotoxic effect of TTR-T4, TTR-ol and TT-
fib to HDFα cells performed by the MTT reduction assay. The values shown are normalized against the 
buffer control (n=3, mean ±s.d.). 
 
 
 
 
 
Table S I: Cumulative calcium fractional variation relative to vehicle in HL-1 cardiomyocytes  
 
External solution (n) mean±s.e.m. P value 
(Tukey's multiple comparisons test)
Veh (51) vs. TTT-ol (26) -9.1·10-5±2.0 vs. 42.9±3.8 <0.001 
Veh (51) vs. TTR-fib (17) -9.1·10-5±2.0 vs. 22.3±1.5 <0.001 
Veh (51) vs. TTR-ol 0Ca (16) -9.1·10-5±2.0 vs. 16.3±1.2 <0.01 
Veh (51) vs. TTR-fib 0Ca (41) -9.1·10-5±2.0 vs. 11.6±2.6 <0.001 
Veh (51) vs. TTR-T4 0Ca (42) -9.1·10-5±2.0 vs. -11.7±1.0 <0.001 
Veh (51) vs. TTR-ol Rya (14) -9.1·10-5±2.0 vs. 20.7±1.4 <0.001 
TTR (12) vs. TTR-ol (26) 2.5±1.8 vs. 42.9±3.8 <0.001 
TTR (12) vs. TTR-fib (17) 2.5±1.8 vs. 22.3±1.5 <0.05 
TTR-ol (26) vs. TTR-fib (17) 42.9±3.8 vs. 22.3±1.5 <0.001 
TTR-ol (26) vs. TTR-T4 (33) 42.9±3.8 vs. 4.0±3.0 <0.001 
TTR-ol (26) vs. TTR-ol 0Ca (16) 42.9±3.8 vs. 16.3±1.2 <0.001 
TTR-ol (26) vs. TTR-fib 0Ca (41) 42.9±3.8 vs. 11.6±2.6 <0.001 
TTR-ol (26) vs. TTR-T4 0Ca (42) 42.9±3.8 vs. -11.7±1.0 <0.001 
TTR-ol (26) vs. TTR-ol Rya (14) 42.9±3.8 vs. 20.7±1.4 <0.001 
TTR-ol (26) vs. TTR-ol 2APB (23) 42.9±3.8 vs. 6.2±0.4 <0.001 
TTR-ol (26) vs. TTR-fib Rya (20) 42.9±3.8 vs. -0.8±2.7 <0.001 
TTR-ol (26) vs. TTR-fib 2APB (18) 42.9±3.8 vs. 9.1±1.2 <0.001 
TTR-ol (26) vs. TTR-T4 Rya (29) 42.9±3.8 vs. -7.4±1.5 <0.001 
TTR-ol (26) vs. TTR-T4+2APB (33) 42.9±3.8 vs. -6.9±1.6 <0.001 
TTR-fib (17) vs. TTR-T4 (33) 22.3±1.5 vs. 4.0±3.0 <0.01 
TTR-fib (17) vs. TTR-T4 0Ca (42) 22.3±1.5 vs. -11.7±1.0 <0.001 
TTR-fib (17) vs. TTR-ol 2APB (23) 22.3±1.5 vs. 6.2±0.4 <0.05 
TTR-fib (17) vs. TTR-fib Rya (20) 22.3±1.5 vs. -0.8±2.7 <0.001 
TTR-fib (17) vs. TTR-T4 Rya (29) 22.3±1.5 vs. -7.4±1.5 <0.001 
TTR-fib (17) vs. TTR-T4 2APB (33) 22.3±1.5 vs. -6.9±1.6 <0.001 
TTR-T4 (33) vs. TTR-T4 0Ca (42) 4.0±3.0 vs. -11.7±1.0 <0.001 
TTR-T4 (33) vs. TTR-ol Rya (14) 4.0±3.0 vs. 20.7±1.4 <0.05 
TTR-ol 0Ca (16) vs. TTR-T4 0Ca (42) 16.3±1.2 vs. -11.7±1.0 <0.001 
TTR-ol 0Ca (16) vs. TTR-fib Rya (20) 16.3±1.2 vs. -0.8±2.7 <0.05 
TTR-ol 0Ca (16) vs. TTR-T4 Rya (29) 16.3±1.2 vs. -7.4±1.5 <0.001 
TTR-ol 0Ca (16) vs. TTR-T4 2APB (33) 16.3±1.2 vs. -6.9±1.6 <0.001 
TTR-fib 0Ca (41) vs. TTR-T4 0Ca (42) 11.6±2.6 vs. -11.7±1.0 <0.001 
TTR-fib 0Ca (41) vs. TTR-T4 Rya (29) 11.6±2.6 vs. -7.4±1.5 <0.001 
TTR-fib 0Ca (41) vs. TTR-T4 2APB (33) 11.6±2.6 vs. -6.9±1.6 <0.001 
TTR-T4 0Ca (42) vs. TTR-ol Rya (14) -11.7±1.0 vs. 20.7±1.4 <0.001 
TTR-T4 0Ca (42) vs. TTR-ol 2APB (23) -11.7±1.0 vs. 6.2±0.4 <0.001 
TTR-T4 0Ca (42) vs. TTR-fib 2APB (18) -11.7±1.0 vs. 9.1±1.2 <0.001 
TTR-ol Rya (14) vs. TTR-fib Rya (20) 20.7±1.4 vs. -0.8±2.7 <0.01 
TTR-ol Rya (14) vs. TTR-T4 Rya (29) 20.7±1.4 vs. -7.4±1.5 <0.001 
TTR-ol Rya (14) vs. TTR-T4 2APB (33) 20.7±1.4 vs. -6.9±1.6 <0.001 
TTR-ol 2APB (23) vs. TTR-T4 Rya (29) 6.2±0.4 vs. -7.4±1.5 <0.05 
TTR-ol 2APB (23) vs. TTR-T4 2APB (33) 6.2±0.4 vs. -6.9±1.6 <0.05 
TTR-fib 2APB (18) vs. TTR-T4 Rya (29) 9.1±1.2 vs. -7.4±1.5 <0.01 
TTR-ol 2APB (23) vs. TTR-T4 2APB (33) 6.2±0.4 vs. -6.9±1.6 <0.01 
 
 
Table S II: Amplitude fractional variation of calcium transient relative to initial value in mice 
ventricular cardiomyocytes  
External solution (n)/time 
(minute)  
mean±s.e.m. P value 
(Tukey's multiple 
comparisons test)
Veh (18)/0 vs. Veh (18)/5 -0.012±0.012 vs. -8.59±2.90 ns 
Veh (18)/0 vs. Veh (18)/10 -0.012±0.012 vs. -36.09±4.27 <0.001 
Veh (18)/0 vs. Veh (18)/15 -0.012±0.012 vs. -49.85±4.29 <0.001 
Veh(18)/0 vs. Veh (18)/20 -0.012±0.012 vs. -60.62±4.19 <0.001 
Veh (18)/0 vs. TTR-ol (14)/0 -0.012±0.012 vs. -1.33·10-5±1.66·10-5 ns 
Veh (18)/0 vs. TTR (13)/0 -0.012±0.012 vs. 2.059·10-5±4.038·10-5 ns 
Veh (18)/0 vs. TTR-fib (19)/0 -0.012±0.012 vs. 6.25·10-4±4.93·10-4 ns 
Veh (18)/5 vs. Veh (18)/10 -8.59±2.90 vs. -36.09±4.27 <0.05 
Veh (18)/5 vs. Veh (18)/15 -8.59±2.90 vs. -49.85±4.29 <0.001 
Veh (18)/5 vs. Veh (18)/20 -8.59±2.90 vs. -60.62±4.19 <0.001 
Veh (18)/5 vs. TTR-fib (19)/5 -8.59±2.90 vs. 18.39±5.64 <0.05 
Veh (18)/10 vs. Veh (18)/15 -36.09±4.27 vs. -49.85±4.29 ns 
Veh (18)/10 vs. Veh (18)/20 -36.09±4.27 vs. -60.62±4.19 ns 
Veh (18)/10 vs. TTR-ol (14)/10 -36.09±4.27 vs. -2.01±7.90 <0.001  
Veh (18)/10 vs. TTR-fib (19)/10 -36.09±4.27 vs. -9.82±7.87 <0.05 
Veh (18)/15 vs. Veh (18)/20 -49.85±4.29 vs. -60.62±4.19 ns 
Veh (18)/15 vs. TTR-ol (14)/15 -49.85±4.29 vs. -15.68±7.57 <0.001 
Veh (18)/15 vs. TTR (13)/15 -49.85±4.29 vs. -44.51±6.13 ns 
Veh (18)/15 vs. TTR-fib (19)/15 -49.85±4.29 vs. -30.47±26.14 ns 
Veh (18)/20 vs. TTR-ol (14)/20 -60.62±4.19 vs. -26.72±7.88 <0.001 
Veh (18)/20 vs. TTR (13)/20 -60.62±4.19 vs. -56.19±5.74 ns 
Veh (18)/20 vs. TTR-fib (19)/20 -60.62±4.19 vs. -46.49±7.83 ns 
TTR-ol (14)/0 vs. TTR (13)/0 -1.33·10-5±1.66·10-5 vs. 2.06·10-5±4.04·10-5 ns 
TTR-ol (14)/0 vs. TTR-fib (19)/0 -1.33·10-5±1.66·10-5 vs. 6.25·10-4±4.93·10-4 ns 
TTR-ol (14)/5 vs. TTR (13)/5 54.47±10.30 vs. -18.50±4.85 <0.001 
TTR-ol (14)/5 vs. TTR-fib (19)/5 54.47±10.30 vs. 18.39±5.64 <0.001 
TTR-ol (14)/10 vs. TTR (13)/10 -2.01±7.90 vs. 29.26±4.48 ns 
TTR-ol (14)/10 vs. TTR-fib 
(19)/10 
-2.01±7.90 vs. -9.82±7.87
ns 
TTR-ol (14)/15 vs. TTR (13)/15 -15.68±7.57 vs. -44.51±6.13 ns 
TTR-ol (14)/15 vs. TTR-fib 
(19)/15 
-15.68±7.57 vs. -30.47±26.14
ns 
TTR-ol (14)/20 vs. TTR (13)/20 -26.72±7.88 vs. -56.19±5.74 ns 
TTR-ol (14)/20 vs. TTR-fib 
(19)/20 
-26.72±7.88 vs. -46.49±7.83
ns 
TTR (13)/0 vs. TTR-fib (19)/0 2.06·10-5±4.04·10-5 vs. 6.25·10-4±4.93·10-4 ns 
TTR (13)/5 vs. TTR-fib (19)/5 -18.50±4.85 vs. 18.39±5.64 <0.001 
TTR (13)/10 vs. TTR-fib (19)/10 29.26±4.48 vs. -9.82±7.87 ns 
TTR (13)/15 vs. TTR-fib (19)/15 -44.51±6.13 vs. -30.47±26.14 ns 
TTR (13)/20 vs. TTR-fib (19)/20 -56.19±5.74 vs. -46.49±7.83 ns 
 
 
Table S III: Baseline fractional variation of calcium transient relative to initial value in mice 
ventricular cardiomyocytes  
Time 
(min) 
Vehicle (mean±s.e.m.) 
n=18 
TTR  
(mean±s.e.m.) 
n=13
TTR-ol 
(mean±s.e.m.) 
n=14
TTR-fib 
(mean±s.e.m.) 
n=19
0 -0.0075±0.0074 2.9·10-10±7.5·10-9 -1.4·10-6±5.2·10-6 9.6·10-8±4.9·10-4
5 3.1±0.6 -1.5±0.7 1.2±1.5 3.0±5.6
10 0.2±1.7 1.4±0.7 0.078±0.33 6.7±7.9
15 13.0±5.4 3.2±1.6 13.0±7.4 5.0±26.1
20 23.2±6.4 16.1±3.0 19.4±9.9 10.6±7.8
 
Table S IV: Time to peak fractional variation of calcium transient relative to initial value measured in 
mice ventricular cardiomyocytes  
Time 
(min) 
Vehicle (mean±s.e.m.) 
n=18 
TTR  
(mean±s.e.m.) 
n=13
TTR-ol 
(mean±s.e.m.) 
n=14
TTR-fib 
(mean±s.e.m.) 
n=19
0 9.7·10-7±1.2·10-6 1.5·10-6±1.5·10-6 1.9·10-7±1.1·10-6 4.7·10-7±9.6·10-7
5 23.3±13.5 10.9±7.7 11.4±3.5 6.7±3.8
10 32.7±18.5 15.8±6.5 19.7±10.9 8.6±7.1
15 85.6±52.8 26.8±12.8 60.3±10.2 60.0±6.7
20 225.8±83.1 189.2± 26.3 166.3±16.7 150.73±12.4
 
Table S V: 50% decay time fractional variation of calcium transient relative to initial value in mice 
ventricular cardiomyocytes  
Time 
(min) 
Vehicle (mean±s.e.m.) 
n=18 
TTR  
(mean±s.e.m.) 
n=13
TTR-ol 
(mean±s.e.m.) 
n=14
TTR-fib 
(mean±s.e.m.) 
n=19
0 8.3·10-7±1.03·10-6 2.3·10-7±4.0·10-7 3.1·10-8±3.3·10-7 5.9·10-7±3.3·10-7
5 14.0±12.6 -2.3±1.6 -3.9±3.0 5.0±2.4
10 17.0±15.3 -7.4±2.8 5.3±5.7 7.4±4.8
15 40.2±23.3 10.6±8.6 16.8±6.1 6.8±4.7
20 202.8±81.4 125.8± 35.1 110.6±25.6 100.4±24.6
 
 
